Table 2.
Second dose adverse vaccine symptoms by brand and age
| 30–50 |
70+ |
|||||
|---|---|---|---|---|---|---|
| BNT162b2 | mRNA-1273 | p | BNT162b2 | mRNA-1273 | pa | |
| n (%)b | 177 | 147 | 608 | 218 | ||
| Completed ≥1 diary | 140 (79.1) | 122 (83.0) | 0.46 | 498 (81.9) | 180 (82.6) | 0.91 |
| Redness near injection site | 18 (12.9) | 31 (25.4) | 0.015 | 52 (10.4) | 30 (16.7) | 0.039 |
| Swelling near injection site | 39 (27.9) | 40 (32.8) | 0.46 | 61 (12.2) | 51 (28.3) | <0.0001 |
| Hives (not at injection site) | 12 (8.6) | 13 (10.7) | 0.72 | 27 (5.4) | 11 (6.1) | 0.88 |
| Pain near injection site | 136 (97.1) | 118 (96.7) | 0.99 | 421 (84.5) | 162 (90.0) | 0.092 |
| Any malaise | 86 (61.4) | 108 (88.5) | <0.0001 | 188 (37.8) | 92 (51.1) | 0.0024 |
| Any headaches | 88 (62.9) | 99 (81.1) | 0.0018 | 162 (32.5) | 72 (40.0) | 0.086 |
| Any fatigue | 112 (80.0) | 115 (94.3) | 0.0014 | 297 (59.6) | 120 (66.7) | 0.12 |
| Any chills | 41 (29.3) | 76 (62.3) | <0.0001 | 34 (6.8) | 42 (23.3) | <0.0001 |
| Any muscle aches or pains | 80 (57.1) | 97 (79.5) | 0.00020 | 221 (44.4) | 107 (59.4) | 0.00073 |
| Any joint aches or pains | 42 (30.0) | 68 (55.7) | <0.0001 | 128 (25.7) | 70 (38.9) | 0.0012 |
| Any nausea | 42 (30.0) | 63 (51.6) | 0.00058 | 68 (13.7) | 42 (23.3) | 0.0037 |
| Any fevers | 17 (12.1) | 51 (41.8) | <0.0001 | 17 (3.4) | 19 (10.6) | 0.00052 |
| Other serious problem related to the vaccine | 17 (12.1) | 34 (27.9) | 0.0023 | 36 (7.2) | 27 (15.0) | 0.0034 |
| ≥1 moderate or severe symptom | 104 (74.3) | 113 (92.6) | 0.00017 | 170 (34.1) | 95 (52.8) | <0.0001 |
a
p values are from chi-square tests.
b
The n (%) are the proportions of those completing the diary who reported each of the symptoms.